NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols

@article{Bratasz2007NCX4040AN,
  title={NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols},
  author={Anna Bratasz and Karuppaiyah Selvendiran and Tomasz Wasowicz and Andrey A. Bobko and Valery V Khramtsov and Louis Joseph Ignarro and Periannan Kuppusamy},
  journal={Journal of Translational Medicine},
  year={2007},
  volume={6},
  pages={9 - 9}
}
Ovarian carcinoma is the leading cause of mortality among gynecological cancers in the world. The high mortality rate is associated with lack of early diagnosis and development of drug resistance. The antitumor efficacy and mechanism of NCX-4040, a nitric oxide-releasing aspirin derivative, against ovarian cancer is studied. NCX-4040, alone or in combination with cisplatin (cis-diamminedichloroplatinum, cDDP), was studied in cisplatin-sensitive (A2780 WT) and cisplatin-resistant (A2780 cDDP… CONTINUE READING